Palvella Therapeutics (PVLA) Competitors $38.62 -0.01 (-0.03%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock PVLA vs. AUPH, CVAC, PHVS, WVE, CALT, NTLA, ABCL, GPCR, ARDX, and ELVNShould you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include Aurinia Pharmaceuticals (AUPH), CureVac (CVAC), Pharvaris (PHVS), WAVE Life Sciences (WVE), Calliditas Therapeutics AB (publ) (CALT), Intellia Therapeutics (NTLA), AbCellera Biologics (ABCL), Structure Therapeutics (GPCR), Ardelyx (ARDX), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry. Palvella Therapeutics vs. Its Competitors Aurinia Pharmaceuticals CureVac Pharvaris WAVE Life Sciences Calliditas Therapeutics AB (publ) Intellia Therapeutics AbCellera Biologics Structure Therapeutics Ardelyx Enliven Therapeutics Aurinia Pharmaceuticals (NASDAQ:AUPH) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings. Is AUPH or PVLA more profitable? Aurinia Pharmaceuticals has a net margin of 16.11% compared to Palvella Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 14.27% beat Palvella Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aurinia Pharmaceuticals16.11% 14.27% 9.93% Palvella Therapeutics N/A -60.29%-43.30% Do analysts prefer AUPH or PVLA? Aurinia Pharmaceuticals currently has a consensus target price of $11.50, indicating a potential upside of 28.78%. Palvella Therapeutics has a consensus target price of $47.50, indicating a potential upside of 22.99%. Given Aurinia Pharmaceuticals' higher probable upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has stronger earnings & valuation, AUPH or PVLA? Aurinia Pharmaceuticals has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurinia Pharmaceuticals$247.30M4.88$5.75M$0.2831.89Palvella Therapeutics$42.81M9.98-$17.43M-$12.10-3.19 Does the media refer more to AUPH or PVLA? In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 4 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 0.93 beat Palvella Therapeutics' score of 0.87 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in AUPH or PVLA? 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 20.5% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, AUPH or PVLA? Aurinia Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. SummaryAurinia Pharmaceuticals beats Palvella Therapeutics on 10 of the 16 factors compared between the two stocks. Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PVLA vs. The Competition Export to ExcelMetricPalvella TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$427.14M$3.04B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-3.1921.1828.1120.03Price / Sales9.98339.43461.37103.88Price / CashN/A43.2336.5559.01Price / Book6.928.368.655.90Net Income-$17.43M-$55.19M$3.25B$258.66M7 Day Performance30.87%5.89%4.21%2.22%1 Month Performance80.97%17.63%10.82%12.76%1 Year PerformanceN/A5.09%34.70%19.36% Palvella Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PVLAPalvella Therapeutics1.4251 of 5 stars$38.620.0%$47.50+23.0%N/A$427.14M$42.81M-3.19N/AAUPHAurinia Pharmaceuticals2.9982 of 5 stars$8.85-1.6%$11.50+29.9%+63.1%$1.21B$235.13M24.30300Upcoming EarningsCVACCureVac4.7508 of 5 stars$5.48+1.3%$6.83+24.7%+51.1%$1.21B$579.18M5.88880Positive NewsPHVSPharvaris1.44 of 5 stars$23.00+0.0%$36.20+57.4%+12.3%$1.20BN/A0.0030News CoverageWVEWAVE Life Sciences4.5582 of 5 stars$7.82+1.4%$20.15+157.7%+36.4%$1.20B$108.30M0.00240Positive NewsUpcoming EarningsHigh Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180NTLAIntellia Therapeutics4.5172 of 5 stars$11.96+4.2%$33.37+179.0%-50.1%$1.19B$57.88M0.00600News CoverageInsider TradeABCLAbCellera Biologics2.2255 of 5 stars$4.06+3.0%$8.75+115.5%+66.8%$1.18B$28.83M0.00500High Trading VolumeGPCRStructure Therapeutics2.952 of 5 stars$19.60+1.9%$76.17+288.6%-49.6%$1.10BN/A0.00136Positive NewsARDXArdelyx4.0215 of 5 stars$4.60+2.2%$10.89+136.7%-22.4%$1.08B$333.61M0.0090ELVNEnliven Therapeutics2.6313 of 5 stars$21.46-0.9%$41.20+92.0%-8.6%$1.06BN/A0.0050Insider Trade Related Companies and Tools Related Companies AUPH Competitors CVAC Competitors PHVS Competitors WVE Competitors CALT Competitors NTLA Competitors ABCL Competitors GPCR Competitors ARDX Competitors ELVN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PVLA) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
